date of comment,main comment,comment,depth,PTR Sentiment,Flair Outlook,Flair Sentiment
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm","Current price as I write this is $26.82. I looked into buying, and I just don't see buying it. Am I missing something?Yes, these are well known brands and it's pretty straightfoward to project revenue and earnings because the sales are already there. There is also a ton of competition in these products and I feel JnJ is spinning off the lowest-margin leg of their business.With 10% earnings on revenue, I get a current P/E ratio of about 34-35. Other consumer brands like P&G sit at about 27. That means a similar target for JVUE would be about $21/share. No where near $26.82.What am I missing that makes this so great to get in on?",0,0.551,NEGATIVE,1.0
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",You are so so right.,1,0.515,POSITIVE,0.996
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm","How will this impact JNJ stock price? I know I‚Äôll pick up KVUE as a JNJ holder but I‚Äôm not sure if this has the same effect as a split or dividend.I saw elsewhere that the KVUE shares were going to be priced at $20-$23, so I am not sure if that means JNJ will fall accordingly or if the IPO is a cash infusion and JNJ stays around the same price. First time in spin-off territory for me.",0,0.525,NEGATIVE,0.996
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",Do you know how much kenvue JNJ shareholders get?,1,0.524,NEGATIVE,0.973
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",Not yet. Still reading the prospectus and I think the answer is going to depend on the valuation determined at IPO. Kenvue is going to be $22/share tomorrow and JnJ will control 90%ish of the shares.,2,0.518,NEGATIVE,0.99
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",Wonder why the info on how much jnj shareholders get is so hard to find? I‚Äôve been looking and haven‚Äôt found a thing.,3,0.509,NEGATIVE,0.998
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm","My understanding, as a layperson and idiot, is that JNJ is holding 90+% of stock and the other 10% is what is being traded currently. The special dividend to JNJ shareholders will be a distribution of the 90% in the form of KVUE stock. How much that will be will be dependent on the KVUE valuation in relation to the dividend. I expect the stock price of JNJ to go down in proportion to the special dividend amount related to the valuation of KVUE when that distribution takes place. I‚Äôm not sure when that will be or how much it will be, but I‚Äôm ok waiting and accepting the diversification of my portfolio with a new consumer staples holding.Agree with u/angrypuppy35 and u/rtg12 that this shouldn‚Äôt be so difficult to figure out. The answer may be in the prospectus and finance textbooks, though. It‚Äôs on me to be more educated.",4,0.534,NEGATIVE,0.999
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",You‚Äôd think communication to shareholders would be a top priority.,4,0.524,NEGATIVE,0.749
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",Read the prospectus linked above and the Barron's article under JNJ news. Other than that I cannot tell you more.I can say that Kenvue gets overseas Talc problems whereas JNJ gets US + Canada.,1,0.507,NEGATIVE,0.975
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",I will be a buyer. Maybe not IPO but once it starts trading.üòÉEdited to Add:Go to JNJ ticker for further DD. Barron's is all over this. We shall see.,0,0.51,NEGATIVE,1.0
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm","KVUE opens today w/the CEO ringing the opening bell. We'll see if the market has an appetite for a big IPO (seems a bit doubtful in this climate and makes me wonder about the timing). After the IPO, J&J still owns just over 90% of the company. Will they be big sellers over the next year or two?",0,0.575,POSITIVE,0.934
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",I hope it tanks!! That way I do not have to chase it. But I suspect it will open in the 40s.....yikes!!,1,0.506,NEGATIVE,0.805
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",Excited for this one. Order is in!,1,0.598,POSITIVE,1.0
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm","How did you fair on this, will you keep it for years to come?",2,0.529,POSITIVE,0.878
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",Any idea where to purchase Kenvue shares? Don't see them on Trading 212 etc.,0,0.516,NEGATIVE,0.978
,"Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow NEW BRUNSWICK, N.J., APRIL 24, 2023 ‚Äì Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (‚ÄúKenvue‚Äù), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (‚ÄúIPO‚Äù) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol ‚ÄúKVUE.‚Äù After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue‚Äôs common stock, representing 91.9% of the total outstanding shares of Kenvue‚Äôs common stock (or 90.8% if the underwriters exercise in full their over-allotment option). Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI ‚Äì Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO. A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com. ETA: prospectus is here https://www.sec.gov/Archives/edgar/data/1944048/000162828023000234/kenvues-1.htm",It is under symbol KVUE. It did not start trading till noon yesterday on NYSE. I have it on TDAmeritrade.It may not show up till the 9th because the IPO period is May 4th-8th. I do not use Trading 212 so no idea.Good luck.,1,0.531,NEGATIVE,0.999
